DGIdb - SARACATINIB Drug Record

SARACATINIB chembl:CHEMBL217092 Antineoplastic

Alternate Names:

AZ-10353926
AZD-0530
SARACATINIB
AZD0530
pubchem.compound:10302451
chembl:CHEMBL217092
drugbank:11805
chemidplus:379231-04-6

Drug Info:

Drug Class	Kinase Inhibitors

(3 More Sources)

Publications:

Murray CW et al., 2015, Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors., ACS Med Chem Lett
Saha et al., 2016, Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma., Cancer Discov
Crystal et al., 2014, Patient-derived models of acquired resistance can identify effective drug combinations for cancer., Science
Powles et al., 2016, A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)., Ann. Oncol.
Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
Girotti et al., 2013, Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma., Cancer Discov
Ichihara et al., 2017, SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer., Cancer Res.

SARACATINIB DDR2

Interaction Score: 2.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26191369

Sources:
DTC
SARACATINIB IDH2

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type intrahepatic cholangiocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
27231123

Sources:
JAX-CKB
SARACATINIB VHL

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type no benefit

PMIDs:
26802156

Sources:
JAX-CKB
SARACATINIB SRC

Interaction Score: 0.64

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

combination therapy Cediranib + Saracatinib

Indication/Tumor Type renal clear cell carcinoma

PMIDs:
25394791 26802156

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions TTD
SARACATINIB BCR

Interaction Score: 0.43

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes Targets BCR-ABL fusion protein

PMIDs:
None found

Sources:
TALC
SARACATINIB ALK

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Saracatinib + Ceritinib

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
25394791

Sources:
JAX-CKB
SARACATINIB ABL1

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
SARACATINIB KRAS

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type intrahepatic cholangiocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
26725216 27231123

Sources:
JAX-CKB
SARACATINIB BRAF

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23242808

Sources:
JAX-CKB
SARACATINIB EGFR

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
28416483

Sources:
JAX-CKB
SARACATINIB IDH1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
27231123

Sources:
JAX-CKB
SARACATINIB YES1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: SARACATINIB
- Version: 20-Jun-2017
Alternate Names:

AZD0530 Development Name

SARACATINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
DTC: SARACATINIB
- Version: 02-September-2020
Alternate Names:

CHEMBL217092 ChEMBL Drug ID

Drug Info:

Publications:

Murray CW et al., 2015, Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors., ACS Med Chem Lett

JAX-CKB: Saracatinib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Girotti et al., 2013, Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma., Cancer Discov

Ichihara et al., 2017, SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer., Cancer Res.

Saha et al., 2016, Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma., Cancer Discov

TALC: SARACATINIB
- Version: 12-May-2016
Alternate Names:

SARACATINIB Primary Drug Name

SARACATINIB Drug Generic Name

AZD0530 Drug Synonym

Drug Info:

Publications:
TTD: AZD0530
- Version: 2020.06.01
Alternate Names:

D0M0XB TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL217092
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL217092
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	intrahepatic cholangiocarcinoma
Response Type	sensitive
Approval Status	Preclinical

Evidence Type	Actionable
Approval Status	Phase II
Response Type	no benefit

Notes
combination therapy	Cediranib + Saracatinib
Indication/Tumor Type	renal clear cell carcinoma

combination therapy	Saracatinib + Ceritinib
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

Mechanism of Interaction	Tyrosine-protein kinase ABL inhibitor
Direct Interaction	yes

Indication/Tumor Type	melanoma
Response Type	sensitive
Approval Status	Preclinical

SARACATINIB	Primary Drug Name
SARACATINIB	Drug Generic Name
AZD0530	Drug Synonym

SARACATINIB Drug Record

SARACATINIB chembl:CHEMBL217092 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26191369

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type intrahepatic cholangiocarcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 27231123

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Phase II Response Type no benefit

PMIDs: 26802156

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes combination therapy Cediranib + Saracatinib Indication/Tumor Type renal clear cell carcinoma

PMIDs: 25394791 26802156

Sources: TALC MyCancerGenome JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Targets BCR-ABL fusion protein

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Saracatinib + Ceritinib Indication/Tumor Type non-small cell lung carcinoma Response Type sensitive

PMIDs: 25394791

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type intrahepatic cholangiocarcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 26725216 27231123

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Preclinical

PMIDs: 23242808

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type sensitive

PMIDs: 28416483

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

PMIDs: 27231123

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: DTC

MyCancerGenome: SARACATINIB

Alternate Names: AZD0530 Development Name SARACATINIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

DTC: SARACATINIB

Alternate Names: CHEMBL217092 ChEMBL Drug ID

Drug Info:

Publications: Murray CW et al., 2015, Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors., ACS Med Chem Lett

JAX-CKB: Saracatinib

Alternate Names:

Drug Info:

TALC: SARACATINIB

Alternate Names: SARACATINIB Primary Drug Name SARACATINIB Drug Generic Name AZD0530 Drug Synonym

Drug Info:

Publications:

TTD: AZD0530

Alternate Names: D0M0XB TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL217092

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL217092

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
26191369

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type intrahepatic cholangiocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
27231123

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type no benefit

PMIDs:
26802156

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

combination therapy Cediranib + Saracatinib

Indication/Tumor Type renal clear cell carcinoma

PMIDs:
25394791 26802156

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes Targets BCR-ABL fusion protein

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Saracatinib + Ceritinib

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
25394791

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type intrahepatic cholangiocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
26725216 27231123

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23242808

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
28416483

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
27231123

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
DTC

Alternate Names:

AZD0530 Development Name

SARACATINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Alternate Names:

CHEMBL217092 ChEMBL Drug ID

Publications:

Murray CW et al., 2015, Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors., ACS Med Chem Lett

Alternate Names:

SARACATINIB Primary Drug Name

SARACATINIB Drug Generic Name

AZD0530 Drug Synonym

Alternate Names:

D0M0XB TTD Drug ID